Target intelligence / Profile preview

BCL11A erythroid-specific enhancer

Molecular classification
Other, Non-coding regulatory DNA element, Enhancer element
01

Overview

The BCL11A erythroid-specific enhancer is a non-coding regulatory DNA element located in intron 2 of the human BCL11A gene. It functions as a developmentally and lineage-specific enhancer, regulating BCL11A expression exclusively in erythroid (red blood cell) lineage cells. By controlling the transcription of BCL11A in erythroid cells, the enhancer is a key determinant of the fetal-to-adult hemoglobin switch, as BCL11A protein represses fetal (gamma-globin) hemoglobin expression. Disruption of this enhancer via genome editing in hematopoietic stem cells has emerged as a highly promising therapeutic strategy to induce fetal hemoglobin and treat disorders such as sickle cell disease and beta-thalassemia. Editing the enhancer enables selective reduction of BCL11A in erythroid cells, sparing its critical functions in other tissues, such as B-lymphocyte development. This approach preserves hematopoietic stem cell self-renewal and function, addressing safety concerns associated with complete BCL11A knockout. The first FDA-approved CRISPR/Cas9 gene therapy, exagamglogene autotemcel (Casgevy), targets this enhancer to treat sickle cell disease and transfusion-dependent beta-thalassemia.

Other names
BCL11A enhancerBCL11A intron 2 erythroid enhancerBCL11A erythroid enhancerBCL11A enhancer regulatory DNA sequencesBCL11A +58-kb enhancerBCL11A +55-kb enhancer
02

Mechanism of action

CRISPR-Cas9-mediated disruption of the erythroid-specific enhancer of BCL11A, which reduces BCL11A expression in erythroid cells and reactivates fetal hemoglobin (HbF) production.

03

Biological functions

OtherRegulation of gene expressionErythroid lineage-specific gene regulationFetal-to-adult hemoglobin switching
04

Disease associations

OtherSickle cell diseaseBeta-thalassemiaHemoglobinopathies
05

Safety considerations

Off-target genome editing riskNeutrophil engraftment failureProlonged time to platelet engraftmentMyeloablative conditioning-related toxicities (e.g., mucositis, febrile neutropenia, infertility)
06

Interacting drugs

07

Biomarkers

Fetal hemoglobin (HbF) levelgamma-globin expressionBCL11A expression level

Beyond the preview

Go deeper on BCL11A erythroid-specific enhancer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCL11A erythroid-specific enhancer.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call